STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #594 by analyst upside · 2026-06-27
DRUG
Bright Minds Biosciences Inc.
Healthcare · Market Cap $646M · P/E 0x
ANALYST PRICE TARGET
+150.9%
implied upside to consensus target
Current Price $65.79
Consensus Target $165.08
Bull Target $213.39
Bear Target $139.8
Analysts Covering 3
ANALYST CONSENSUS — HOLD
Strong Buy
0
Buy
2
Hold
0
Sell
1
52-Week Low $23.18
52-Week High $123.75
YTD Return -21.2%
FUNDAMENTALS
Market Cap $646M
P/E Ratio (TTM) N/A
Forward P/E -7.8x
EPS (TTM) $-2.49
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $23.18
52-Week High $123.75
Current Price $65.79
Bear Target $139.8
Bull Target $213.39
● Now $65.79 ● Target $165.08
TRADING DATA
Avg Volume 283K
YTD Return -21.2%
Analyst Count 3
Consensus Hold
Upside to Target +150.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Bright Minds Biosciences Inc. (DRUG) is currently trading at $65.79 with a Wall Street consensus price target of $165.08, implying potential upside of 150.9% over the next 12 months. 3 analysts currently cover DRUG, with a consensus rating of Hold — 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $213.39, while the most cautious has a target of $139.8.

DRUG operates in the Healthcare sector with a market capitalisation of $646M. The stock is down 21.2% year-to-date and is currently trading near the lower end of its 52-week range of $23.18 – $123.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for DRUG, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-06-01 31% win rate (48 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-20 14% win rate (7 calls)
Jefferies ● Initiated
Buy 2026-04-13 50% win rate (6 calls)
BTIG reit
Buy → Buy 2026-03-30 38% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-04 31% win rate (48 calls)
BTIG — Reiterated
Buy → Buy 2026-02-17 38% win rate (8 calls)
BTIG — Reiterated
Buy → Buy 2026-01-07 38% win rate (8 calls)
BTIG — Reiterated
Buy → Buy 2026-01-06 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
33
out of 100
Coverage depth
11/30
Consensus clarity
8/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →